文献速递血栓与止血

免疫性血小板减少症成人患者从其他TPO-RA转换为阿伐曲泊帕的安全性、疗效和治疗满意度

Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA.
PubMed 文献 · Blood Adv · 2025-01-01

这项4期多中心开放标签研究纳入60例已接受艾曲泊帕或罗米司亭≥90天且有应答的免疫性血小板减少症成人患者,无洗脱期直接转换为阿伐曲泊帕。结果显示58.3%发生治疗中出现的不良事件、10.0%发生严重不良事件,血小板计数在可接受范围维持,治疗满意度各维度评分从基线至第90天均有提升。

要点

  • 转换为阿伐曲泊帕后58.3%发生治疗中出现的不良事件,10.0%发生严重不良事件。
  • 第90天55.0%患者血小板计数在≥50×10⁹/L且≤200×10⁹/L范围。
  • 治疗满意度问卷各维度评分从基线至第90天均升高。

核心结论

  • 免疫性血小板减少症患者可安全地从其他TPO-RA转换为阿伐曲泊帕,维持足够血小板计数并改善治疗满意度。

研究设计与样本

  • 4期、多中心、开放标签研究,纳入60例已接受艾曲泊帕或罗米司亭≥90天且有应答(2次血小板计数≥50×10⁹/L)的成人免疫性血小板减少症患者,无方案定义的洗脱期直接转换为阿伐曲泊帕。

主要发现

  • 60例入组患者中58.3%发生治疗中出现的不良事件,10.0%发生严重不良事件(1例与阿伐曲泊帕相关[血小板减少,已缓解];5例无关[含1例无关死亡])。
  • 血小板计数≥50×10⁹/L且≤200×10⁹/L的患者比例在基线为51.7%,第15天为31.7%,第30天为55.0%,第60天为60.0%,第90天为55.0%;第15天平均血小板计数256.2×10⁹/L(标准差176.7×10⁹/L)。
  • 治疗满意度问卷各维度评分从基线至第90天升高(平均变化:便利性+13.5;有效性+14.4;总体满意度+14.2;副作用+8.3)。
  • 第90天稳定的阿伐曲泊帕剂量与既往TPO-RA剂量(高或低)之间无相关性。

关键数值与推荐

  • 主要终点为治疗中出现的不良事件和严重不良事件的发生率。
  • 次要终点包括第15、30、60、90天血小板计数在≥50×10⁹/L且≤200×10⁹/L的患者比例,以及治疗满意度问卷各维度从基线至第90天的变化。
  • 研究注册号:NCT04638829。

临床怎么用

  • 原文结论指出免疫性血小板减少症患者可安全地从其他TPO-RA转换为阿伐曲泊帕并维持足够血小板计数,同时治疗满意度改善。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This phase 4, multicenter, open-label study was conducted to evaluate the safety, efficacy, and treatment satisfaction of switching to avatrombopag from another thrombopoietin receptor agonist (TPO-RA) in patients with immune thrombocytopenia (ITP). Adults who had received ≥90 days of treatment with eltrombopag or romiplostim and had a response (2 platelet counts [PCs] ≥50 × 109/L) switched to avatrombopag with no protocol-defined washout period. The primary end point was the incidence of treatment-emergent adverse events (TEAEs) and serious TEAEs. Secondary end points were the proportion of patients who had a PC between ≥50 × 109/L and ≤200 × 109/L (days 15, 30, 60, and 90) and change from baseline in each domain of the self-administered Treatment Satisfaction Questionnaire for Medication (TSQM) to day 90. Among 60 enrolled patients, 58.3% experienced TEAEs and 10.0% experienced serious TEAEs (1 related to avatrombopag [thrombocytopenia that resolved]; 5 unrelated [1 unrelated death]). A PC ≥50 × 109/L to ≤200 × 109/L was reported for 51.7%, 31.7% (mean PC, 256.2 × 109/L [standard deviation, 176.7 × 109/L]), 55.0%, 60.0%, and 55.0% at baseline and on days 15, 30, 60, and 90, respectively. TSQM scores increased from baseline to day 90 across all domains (mean change: convenience, +13.5; effectiveness, +14.4; global satisfaction, +14.2; side effects, +8.3). There was no correlation between stable avatrombopag dose (day 90) and previous TPO-RA dose (high or low). Patients with ITP may safely switch from another TPO-RA to avatrombopag and maintain adequate PCs while experiencing improved treatment satisfaction. This trial was registered at www.ClinicalTrials.gov as #NCT04638829.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tarantino MD, Mosalpuria K, Kolodny S, et al. Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA. Blood Adv. 2025. PMID: 40101243. doi:10.1182/bloodadvances.2024015635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。